PO.TB01.01 · 肿瘤生物学
三种血管内皮标志物在评估皮肤黑色素瘤微血管密度中的比较
Comparison of three vascular endothelial markers in the evaluation of microvessel density in cutaneous melanoma
该海报暂无可下载的资料
AACR 官方页面
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
背景
血管生成是包括恶性黑色素瘤在内的许多实体癌的肿瘤生长、存活和转移的基础。量化肿瘤血管生成的一种方法是使用内皮免疫组化标志物评估微血管密度（MVD）。在常规实践中，抗因子VIII相关抗原、抗CD31和抗CD34均用于此目的，但它们在皮肤黑色素瘤中的相互比较尚不十分明确。我们比较了这三种标志物，以确定在此特定情境下哪种对MVD评估最为有用。
方法
我们采用2015年至2021年间在比勒陀利亚大学收集的存档皮肤黑色素瘤样本，进行了一项分析性比较研究。对来自34例病例的102张组织切片进行了抗因子VIII、抗CD31和抗CD34抗体的免疫组化。三位病理学家针对每种标志物在10个高倍视野（200×放大）中独立计数微血管。使用重复测量方差分析（ANOVA）并进行事后检验对数据进行分析（p<0.05）。
结果
平均MVD分别为：抗CD34 77.33（±29.57），抗CD31 61.67（±34.85），抗因子VIII 58.67（±23.51）。抗CD34显示的微血管显著多于抗CD31或抗因子VIII（p=0.003）。事后分析证实CD31与CD34之间以及CD34与因子VIII之间存在显著差异（p=0.001）。相反，抗CD31和抗因子VIII在微血管检测的敏感性或特异性方面未显示出有意义的差异。
结论
在本系列中，抗CD34在显示皮肤黑色素瘤MVD方面优于抗CD31和抗因子VIII。这与其他实体肿瘤的报道一致，提示CD34倾向于识别更多血管。尽管我们的样本量适中且来自单一中心，但数据支持将抗CD34用作外科病理学中肿瘤内MVD评估的首选标志物，理想情况下应结合临床病理相关性，并在需要时使用补充标志物。
查看英文原文 English abstract
Background
Angiogenesis underpins tumor growth, survival, and metastasis in many solid cancers, including malignant melanoma. One way to quantify tumor angiogenesis is to assess microvessel density (MVD) using endothelial immunohistochemical markers. In routine practice, anti-factor VIII-related antigen, anti-CD31, and anti-CD34 are all used for this purpose, but how they stack up against each other in cutaneous melanoma is still not very clear. We compared these three markers to determine which is the most useful for MVD evaluation in this specific context.
Methods
We conducted an analytical comparative study using archival cutaneous melanoma samples collected between 2015 and 2021 at the University of Pretoria. Immunohistochemistry with anti-factor VIII, anti-CD31, and anti-CD34 antibodies was performed on 102 tissue sections from 34 cases. Three pathologists independently counted the microvessels in 10 high-power fields (200× magnification) for each marker. Data were analyzed using repeated-measures ANOVA with post-hoc testing (p<0.05).
Results
The mean MVDs were 77.33 (±29.57) for anti-CD34, 61.67 (±34.85) for anti-CD31, and 58.67 (±23.51) for anti-factor VIII. Anti-CD34 highlighted significantly more microvessels than anti-CD31 or anti-factor VIII (p=0.003). Post-hoc analysis confirmed significant differences between CD31 and CD34, and between CD34 and factor VIII (p=0.001). In contrast, anti-CD31 and anti-factor VIII did not show a meaningful difference in sensitivity or specificity for microvessel detection.
Conclusion
In this series, anti-CD34 performed better than anti-CD31 and anti-factor VIII in highlighting MVD in cutaneous melanoma. This is in line with reports from other solid tumors, suggesting that CD34 tends to pick up more vessels. While our sample size is modest and drawn from a single center, the data support the use of anti-CD34 as the preferred marker for intratumoral MVD assessment in surgical pathology, ideally alongside clinicopathological correlation and, where needed, complementary markers.
利益披露 Disclosure
N. Moyakhe, None..
B. Mosoane, None..
T. Marutha, None..
R. Marima, None..
Z. Dlamini, None..
M. Bida, None.